Skip to main content

Ligand Pharmaceuticals stock tanks after extremely critical Citron report

Shares of Ligand Pharmaceuticals Inc. fell 17% on Wednesday after Citron Research, headed by famed short seller Andrew Left, called the drug company’s pipeline a ‘pipe dream.’
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.